Brazilian consensus in muscle-invasive and metastatic urothelial carcinoma

ABSTRACT

Urothelial carcinoma is a frequent worldwide malignancy. Poor survival rates in muscle-invasive and metastatic urothelial carcinoma impose major challenges for management. We conducted a consensus meeting to discuss the optimal treatment for urothelial carcinoma in Brazil, which was developed by a panel of multidisciplinary experts consisting of oncologists, urologists and radiation therapists. This paper provides recommendations for perioperative treatment, metastatic disease management, bone directed therapy and genetic counselling in urothelial carcinoma based on the specialists opinions and was classified according to the level of evidence found in the medical literature according to the Oxford classification. The recommendations were based on the available treatments in Brazil to guide health professionals in the management of urothelial carcinoma in low- and middle- income countries with limited access to therapy.

RESUMO

O carcinoma urotelial é uma malignidade mundial frequente. As baixas taxas de sobrevivência no carcinoma urotelial músculo invasivo e metastático impõem grandes desafios em relação ao manejo. Realizamos uma reunião de consenso para discutir o tratamento ideal para o carcinoma urotelial no Brasil, desenvolvido por um painel de especialistas multidisciplinares composto por oncologistas, urologistas e radioterapeutas. Este artigo fornece recomendações para tratamento perioperatório, tratamento da doença metastática, terapia dirigida aos ossos e aconselhamento genético no carcinoma urotelial, com base nas opiniões dos especialistas e foi classificado de acordo com o nível de evidência encontrado na literatura médica, de acordo com a classificação de Oxford. As recomendações foram baseadas nos tratamentos disponíveis no Brasil para orientar os profissionais de saúde no tratamento do carcinoma urotelial em países de baixa e média renda com acesso limitado à terapia.

Keywords:

Urothelial carcinoma - Bladder cancer - Cystectomy - Chemotherapy - muscle-invasive - Metastatic urothelial carcinoma - Upper urinary tract carcinoma

Descritores:

Carcinoma urotelial - Câncer de bexiga - Cistectomia - Quimioterapia músculo invasiva - Carcinoma urotelial metastático - Carcinoma do trato urinário superior

Publication History

Received: 17 September 2019

Accepted: 26 January 2020

Article published online:
10 June 2020

• REFERENCES

• Miyazaki J, Nishiyama H.. Epidemiology of urothelial carcinoma. Int J Urol 2017; Oct; 24 (10) 730-734
• Siegel RL, Miller KD, Jemal A.. Cancer statistics, 2019. CA Cancer J Clin 2019; Jan; 69 (01) 7-34
• Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M. et al Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; Apr; 144 (08) 1941-1953
• World Health Organization (WHO). Cancer Today - Data visualization tools for exploring the global cancer burden in 2018 - GLOBOCAN 2018. Genebra: WHO; 2018. access 2019 May 18 Available from: http://gco.iarc.fr/today/home
• Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Estimativa 2018: incidência de câncer no Brasil. Rio de Janeiro (RJ): INCA; 2017. access 2019 Jun 30 Available from: http://www1.inca.gov.br/estimativa/2018/estimativa-2018.pdf
• Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Huang CC. et al The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003; 98 (08) 1620-1626
• Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017; Jan; 71 (01) 96-108
• Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ. et al Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 2016; 69 (02) 300-310
• Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011; 306 (07) 737-745
• Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P. et al Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000; 86 (02) 289-294
• Witjes JA, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM. et al Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2017; 71 (03) 462-475
• Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P. et al Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; Feb; 63 (02) 234-241
• Heidegger I, Borena W, Pichler R. The role of human papilloma virus in urological malignancies. Anticancer Res 2015; May; 35 (05) 2513-2519
• Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK. et al NCCN Guidelines Insights: bladder cancer, version 5.2018. J Natl Compr Canc Netw 2018; 16 (09) 1041-1053
• Shah BK, Mandal R. Survival trends in metastatic bladder cancer in the United States: a population based study. J Can Res Ther 2015; Jan/Mar; 11 (01) 124-128
• Philips B, Sackett D, Badenoch D, Straus S, Hynes B, Dawes M.. Oxford Centre for evidence-based medicine - levels of evidence (March 2009). 2009 access 2019 Apr 28 Available from: http://www.cebm.net/oxford-centre-evidence-basedmedicine-levels-evidence-march-2009/
• Van der Post RS, Kiemeney LA, Ligtenberg MJ, Witjes JA, Hulsbergen-Van de Kaa CA, Bodmer D. et al Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010; Jul; 47 (07) 464-470
• Duraturo F, Liccardo R, De Rosa M, Izzo P. Genetics, diagnosis and treatment of Lynch syndrome: old lessons and current challenges. Oncol Lett 2019; Mar; 17 (03) 3048-3054
• Kohlmann W, Gruber SB. Lynch syndrome. Synonyms: HNPCC, Hereditary Non-Polyposis Colon Cancer. Washington, DC: GeneReviews; 2004. access 2019 Apr 28 Available from: http://www.ncbi.nlm.nih.gov/books/NBK1211
• Ghosh S.. Cisplatin: the first metal based anticancer drug. Bioorg Chem 2019; Jul; 88: 102925
• de Vos FY, de Wit R. Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy. Ther Adv Med Oncol 2010; Nov; 2 (06) 381-388
• Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G. et al Impact of renal impairment on eligibility for adjuvant cisplatinbased chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; Aug; 107 (03) 506-513
• Sonpavde G, Galsky MD, Latini D, Chen GJ. Cisplatin-ineligible and chemotherapyineligible patients should be the focus of new drug development in patients with advanced bladder cancer. Clin Genitourin Cancer 2014; Apr; 12 (02) 71-73
• Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 2017; 22 (05) 609-619
• Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R. et al Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 2012; Feb; 23 (02) 406-410
• Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK. et al Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol 2011; Jun; 29 (17) 2432-2438
• Birtle AJ, Chester JD, Jones RJ, Johnson M, Hill M, Bryan RT. et al Results of POUT: a phase III randomized trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol 2018; Feb; 36 (Suppl 6): 407
• Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA. et al Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist 2016; Jun; 21 (06) 708-715
• Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Genitourinary Cancer Disease Site Group. et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004; Feb; 171 (2 Pt 1): 561-569
• Advanced Bladder Cancer (ABC). Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; Aug; 48 (02) 202-205 discussion:205-6
• Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL. et al Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; Aug; 349 (09) 859-866
• International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organization for Research and Treatment of Cancer Genito- Urinary Tract Cancer Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; Jun; 29 (16) 2171-2177
• Martinez-Piñeiro JA, Martin MG, Arocena F, Flores N, Roncero CR, Portillo JA. et al Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995; MAr; 153 (3 Pt 2): 964-973
• Soloway MS, Ishikawa S, Taylor T, Ezell G. M-VAC or MVC for the treatment of advanced transitional cell carcinoma: metastatic, induction, and adjuvant. J Surg Oncol Suppl 1989; 1: 40-45
• Van de Putte EE, Mertens LS, Meijer RP, Van Der Heijden MS, Bex A, Van Der Poel HG. et al Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/ cisplatin. World J Urol 2016; 34 (02) 157-162
• Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE. et al Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 2014; Jun; 32 (18) 1895-1901
• Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM. et al Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. JAMA Oncol 2018; Nov; 4 (11) 1535-1542
• Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM. et al Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. J Clin Oncol 2018; Jul; 36 (19) 1949-1956
• Tully CM, Bochner BH, Dalbagni G, Zabor EC, Herr HW, Donat SM. et al Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC- PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): Assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND. J Clin Oncol 2014; Feb; 32 (4 Suppl 1): 355
• Raj GV, Karavadia S, Schlomer B, Arriaga Y, Lotan Y, Sagalowsky A. et al Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle- invasive bladder cancer. Cancer 2011; Jan; 117 (02) 276-282
• Bruins HM, Huang GJ, Cai J, Skinner DG, Stein JP, Penson DF. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J Urol 2009; 182 (05) 2182-2187
• Karl A, Carroll PR, Gschwend JE, Knüchel R, Montorsi F, Stief CG. et al The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol 2009; Apr; 55 (04) 826-835
• Vale CL. Advanced Bladder Cancer (ABC). Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev 2006; Apr; (02) CD006018
• Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003; Mar; 169 (03) 943-945
• Konety BR, Joslyn SA, O'Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the surveillance, epidemiology and end results program data base. J Urol 2003; Mar; 169 (03) 946-950
• Vieweg J, Gschwend JE, Herr HW, Fair WR. The impact of primary stage on survival in patients with lymph node positive bladder cancer. J Urol 1999; Jan; 161 (01) 72-76
• Herr HW, Faulkner JR, Grossman HB, Natale RB, White RV, Sarosdy MF. et al Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004; Jul; 22 (14) 2781-2789
• Quek ML, Sanderson KM, Daneshmand S, Stein JP. The importance of an extended lymphadenectomy in the management of high-grade invasive bladder cancer. Expert Rev Anticancer Ther 2004; 4 (06) 1007-1016
• Koshkin VS, Grivas P. Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research. Transl Androl Urol 2018; 7 (03) 504-507
• Seisen T, Jamzadeh A, Leow JJ, Rouprêt M, Cole AP, Lipsitz SR. et al Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy. JAMA Oncol 2018; Feb; 4 (02) 225-229
• Hanna KS. Updates and novel treatments in urothelial carcinoma. J Oncol Pharm Pract 2019; Apr; 25 (03) 648-656
• Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA. et al ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscleinvasive urothelial carcinoma of the bladder. Eur Urol 2013; Jan; 63 (01) 45-57
• Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP. et al Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combinedmodality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014; Dec; 32 (34) 3801-3809
• Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M. et al Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol 2011; Feb; 29 (06) 733-738
• Atasoy BM, Dane F, Cetin IA, Ozgen Z, Kefeli AU, Ibrahimov R. et al Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients. Clin Transl Oncol 2014; Jan; 16 (01) 91-95
• James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C. et al Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012; 366 (16) 1477-1488
• Canter D, Viterbo R, Kutikov A, Wong YN, Plimack E, Zhu F. et al Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 2011; Jan; 77 (01) 160-165
• Haque W, Lewis GD, Verma V, Darcourt JG, Butler EB, Teh BS. The role of adjuvant chemotherapy in locally advanced bladder cancer. Acta Oncol 2018; 57 (04) 509-515
• Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP. et al The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 2010; Sep; 16 (17) 4461-4467
• Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S. et al Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 1988; Oct; 6 (10) 1590-1596
• Paz-Ares LG, Solsona E, Esteban E, Saez A, Gonzalez-Larriba J, Hevia AAM. et al Randomized phase III trial comparing adjuvant paclitaxel/ gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. J Clin Oncol 2016; 28 (18 Suppl 1): LBA4518
• Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT. et al Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and metaanalysis of randomized trials. Eur Urol 2014; Jul; 66 (01) 42-54
• Pouessel D, Bastuji-Garin S, Houédé N, Vordos D, Loriot Y, Chevreau C. et al Adjuvant chemotherapy after radical cystectomy for urothelial bladder cancer: outcome and prognostic factors for survival in a French multicenter, contemporary cohort. Clin Genitourin Cancer 2017; Feb; 15 (01) e45-e52
• Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG. et al Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 2014; Jun; 120 (12) 1794-1799
• Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA. et al Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010; Jul; 116 (13) 3127-3134
• Yu C, Hequn C, Jinbo C, Feng Z, Xiongbing Z, Jian D. Gemcitabine/cisplatin versus methotrexate/ vinblastine/doxorubicin/cisplatin for muscleinvasive bladder cancer: a systematic review and meta-analysis. J Cancer Res Ther 2018; Oct/ Dec; 14 (06) 1260-1265
• Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J. et al Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicenter, phase 2 trial. Lancet 2017; Jan; 389 (10064): 67-76
• Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T. et al First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017; Nov; 18 (11) 1483-1492
• Von Der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ. et al Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; Sep; 18 (17) 3068-3077
• Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I. et al A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; Jul; 10 (07) 1066-1073
• De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P. et al Randomized phase II/ III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; Jan; 30 (02) 191-199
• Sella A, Kovel S. Combination of gemcitabine and carboplatin in urothelial cancer patients unfit for cisplatin due to impaired renal or cardiac function. Int Braz J Urol 2012; Jan/Feb; 38 (01) 49-56
• Bamias A, Moulopoulos LA, Koutras A, Aravantinos G, Fountzilas G, Pectasides D. et al The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A phase II study of the hellenic cooperative oncology group. Cancer 2006; Jan; 106 (02) 297-303
• Linardou H, Aravantinos G, Efstathiou E, Kalofonos C, Anagnostopoulos A, Deliveliotis C. et al Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group. Urology 2004; Sep; 64 (03) 479-484
• Nogué-Aliguer M, Carles J, Arrivi A, Juan O, Alonso L, Font A. et al Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 2003; May; 97 (09) 2180-2186
• Shannon C, Crombie C, Brooks A, Lau H, Drummond M, Gurney H.. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol 2001; Jul; 12 (07) 947-952
• Di Martino E, Tomlinson DC, Williams SV, Knowles MA. A place for precision medicine in bladder cancer: targeting the FGFRs. Future Oncol 2016; Oct; 12 (19) 2243-2263
• Clinical Trials (US). Study of durvalumab given with chemotherapy, durvalumab in combination with tremelimumab given with chemotherapy, or chemotherapy in patients with unresectable urothelial cancer (NILE). Bethesda (MD): National Library of Medicine (US); 2018. [Sep cited 2019 Aug 21]; NCT03682068:[about 10 screens] Available from: https://clinicaltrials.gov/ct2/show/NCT03682068?term=NCT03682068&rank=1
• Clinical Trials (US). Study of MEDI4736 (durvalumab) with or without tremelimumab versus standard of care chemotherapy in urothelial cancer. Bethesda (MD): National Library of Medicine (US); 2015. [Aug cited 2019 Aug 21]; NCT02516241:[about 8 screens] Available from: https://clinicaltrials.gov/ct2/show/NCT02516241
• Clinical Trials (US). Study of atezolizumab as monotherapy and in combination with platinum-based chemotherapy in participants with untreated locally advanced or metastatic urothelial carcinoma (IMvigor130). Bethesda (MD): National Library of Medicine (US); 2016. [Jun cited 2019 Aug 21]; NCT02807636:[about 11 screens] Available from: https://clinicaltrials.gov/ct2/show/NCT02807636
• Clinical Trials (US). Study of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy alone in urothelial carcinoma (MK- 3475-361/ KEYNOTE-361). Bethesda (MD): National Library of Medicine (US); 2016. [Aug cited 2019 Aug 21]; NCT02853305:[about 9 screens] Available from: https://clinicaltrials.gov/ct2/show/NCT02853305
• Siefker-Radtke AO, Necchi A, Rosenbaum E, Culine S, Burgess EF, O'Donnell PH. et al Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC). J Clin Oncol 2018; 36 (6 Suppl 1): 450
• Galsky MD, Saci A, Szabo P, Wang L, Zhu J, Azrilevich A. et al Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC). J Clin Oncol 2018; 36 (6 Suppl 1): 511
• Siefker-Radtke AO, Necchi A, Park SH, GarciaDonas J, Huddart RA, Burgess EF. et al First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). J Clin Oncol 2018; 36 (15 Suppl 1): 4503
• Agência Nacional de Vigilância Sanitária (ANVISA). Resolução-RE n. 2.692, de 26 de setembro de 2019. Gerência-Geral de Medicamentos e Produtos Biológicos. Diário Oficial da União, Brasília (DF): ANVISA; 2019; [access 2019 Nov 8]; 1(Suppl 1):12. Available from: http://www.in.gov.br/web/dou/-/resolucao-re-n-2.692-de-26-desetembro-de-2019-218910561
• Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L. et al Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017; Mar; 376 (11) 1015-1026
• Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ. et al Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer. J Clin Oncol 2018; Jun; 36 (16) 1579-1587
• Powles T, Durán I, Van Der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U. et al Atezolizumab versus chemotherapy in patients with platinumtreated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2018; Feb; 391 (10122): 748-757
• Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ. et al Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 2017; 3 (09) e172411
• Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J. et al Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017; Mar; 18 (03) 312-322
• Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G. et al Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumcontaining regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; Sep; 27 (27) 4454-4461
• Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E. et al Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2019; Jul; 381 (04) 338-348
• Clinical Trials (US). A study of erdafitinib compared with vinflunine or docetaxel or pembrolizumab in participants with advanced urothelial cancer and selected Fibroblast Growth Factor Receptor (FGFR) gene aberrations. Bethesda (MD): National Library of Medicine (US); 2018. Jan access 2019 Jul 2 NCT03390504 Available from: https://clinicaltrials.gov/ct2/show/NCT03390504
• Froehner M, Hölscher T, Hakenberg OW, Wirth MP. Treatment of bone metastases in urologic malignancies. Urol Int 2014; 93 (03) 249-256
• Zhang C, Liu L, Tao F, Guo X, Feng G, Chen F. et al Bone metastases pattern in newly diagnosed metastatic bladder cancer: a population-based study. J Cancer 2018; 9 (24) 4706-4711
• Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI. et al Long- term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; Oct; 17 (10) 3173-3181
• Body JJ, Bone HG, Boer RH, Stopeck A, Van Poznak C, Damião R. et al Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer 2015; Sep; 51 (13) 1812-1821
• Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA. et al Superiority of denosumab to zoledronic acid for prevention of skeletalrelated events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; Nov; 48 (16) 3082-3092
• Costa L, Fizazi K, Saad F, Brown JE, Von Moos R, Sternberg SOCN. et al Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases. J Clin Oncol 2013; 31 (15 Suppl 1): 5079
• Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR. et al New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 2013; Feb; 63 (02) 309-320
• Leng S, Lentzsch S.. Bone-modifying agents: complicated to use. J Oncol Pract 2018; Aug; 14 (08) 469-470
• Ribeiro GH, Chrun ES, Dutra KL, Daniel FI, Grando LJ. Osteonecrosis of the jaws: a review and update in etiology and treatment. Braz J Otorhinolaryngol 2018; 84 (01) 102-108